BTK and B-cell chronic lymphocytic leukemia: Ibrutinib is a small‐molecule inhibitor of Bruton tyrosine kinase (BTK), a non‐receptor kinase that plays a critical role in the survival of leukaemic B cells in CLL [6, 7].